JAK2突变造血细胞的代谢改变可作为骨髓增殖性肿瘤的治疗靶点
该研究揭示JAK2突变驱动骨髓增殖性肿瘤(MPN)的代谢重编程,小鼠模型出现低血糖、脂肪萎缩和早期死亡,与糖酵解和氧化磷酸化增强相关。高脂饮食改善生存,高糖饮食加重表型;抑制Pfkfb3可逆转低血糖并减少MPN表现,与芦可替尼联用有叠加效应。
要点
- JAK2突变MPN存在系统性代谢改变,包括低血糖和脂肪萎缩。
- 高脂饮食改善MPN小鼠生存,高糖饮食加重疾病表型。
- 抑制Pfkfb3可逆转低血糖并减轻MPN表现,与芦可替尼有叠加效应。
核心结论
- JAK2突变造血细胞的代谢改变参与MPN发病,突变细胞的代谢依赖可成为治疗靶点。
研究设计与样本
- 研究使用JAK2突变驱动的MPN小鼠模型及细胞实验,比较突变与野生型造血干祖细胞的转录组和代谢组。
主要发现
- JAK2突变增强并颠覆MPN细胞代谢活性,体内出现低血糖、脂肪组织萎缩和早期死亡。
- MPN小鼠低血糖与红系造血过度活跃相关,由糖酵解升高和氧化磷酸化增加共同导致。
- 高脂饮食改善生存,高糖饮食加重MPN表型。
- Pfkfb3小分子抑制剂3PO逆转低血糖并减少MPN造血表现,体内外与芦可替尼效应叠加。
- 3PO抑制糖酵解改变氧化还原稳态,导致活性氧积累和凋亡率增加。
临床怎么用
- JAK2突变MPN患者可能需关注代谢状态,如血糖和脂肪组织变化。
- Pfkfb3抑制与芦可替尼联用可能成为MPN的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Increased energy requirement and metabolic reprogramming are hallmarks of cancer cells. We show that metabolic alterations in hematopoietic cells are fundamental to the pathogenesis of mutant JAK2-driven myeloproliferative neoplasms (MPNs). We found that expression of mutant JAK2 augmented and subverted metabolic activity of MPN cells, resulting in systemic metabolic changes in vivo, including hypoglycemia, adipose tissue atrophy, and early mortality. Hypoglycemia in MPN mouse models correlated with hyperactive erythropoiesis and was due to a combination of elevated glycolysis and increased oxidative phosphorylation. Modulating nutrient supply through high-fat diet improved survival, whereas high-glucose diet augmented the MPN phenotype. Transcriptomic and metabolomic analyses identified numerous metabolic nodes in JAK2-mutant hematopoietic stem and progenitor cells that were altered in comparison with wild-type controls. We studied the consequences of elevated levels of Pfkfb3, a key regulatory enzyme of glycolysis, and found that pharmacological inhibition of Pfkfb3 with the small molecule 3PO reversed hypoglycemia and reduced hematopoietic manifestations of MPNs. These effects were additive with the JAK1/2 inhibitor ruxolitinib in vivo and in vitro. Inhibition of glycolysis by 3PO altered the redox homeostasis, leading to accumulation of reactive oxygen species and augmented apoptosis rate. Our findings reveal the contribution of metabolic alterations to the pathogenesis of MPNs and suggest that metabolic dependencies of mutant cells represent vulnerabilities that can be targeted for treating MPNs.
引用
- Rao TN, Hansen N, Hilfiker J, et al. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019. PMID: 31511238. doi:10.1182/blood.2019000162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。